Freya Biosciences Advances FB301 Program and Ramps Up Investor Outreach

Freya Biosciences is an early-stage women’s health company developing microbiome-based therapies for infertility and related conditions, and this is a weekly summary of notable news. The company continued to spotlight its focus on treating inflammation and immune dysregulation in women, positioning its platform as a differentiated approach in reproductive medicine.

Core to this strategy is FB301, a microbiome therapy for IVF-related embryo implantation failure that recently reported positive Phase 1 topline data. The study showed FB301 was safe and well tolerated while effectively modulating the vaginal microbiome toward a Lactobacillus-dominant state.

According to the data, 50% of women in the highest-dose group converted to a non-dysbiotic microbiome profile at six months versus 11.1% on placebo, meeting primary and secondary endpoints. These results provide early proof-of-concept for Freya’s approach and support further clinical development.

On the back of these findings, FB301 is advancing into Phase 2 trials in the U.S. and Germany in women undergoing assisted reproductive technologies such as frozen embryo transfer, as well as in a bacterial vaginosis population. The program is now described as Phase 2-ready under cleared IND and CTA approvals, broadening Freya’s addressable women’s health markets.

The Phase 1 outcome also serves as validation for the company’s Dyscover platform, which uses multi-omics and a biobank to design microbiome-based interventions aimed at immune dysregulation. Freya plans to build a focused pipeline around FB301 and additional first-in-class candidates targeting IVF failure and preterm birth, though future value will depend on later-stage efficacy and regulatory results.

In parallel with clinical progress, Freya is increasing its scientific and leadership visibility. CSO and co‑founder Johan E.T. van Hylckama Vlieg is scheduled to participate in the Microbes in Women’s Health Congress in Valencia and chair sessions at the 3rd Microbiome PT Summit in Lisbon.

CEO Colleen Acosta was named one of In Vivo’s 2026 Rising Leaders, enhancing the company’s profile in the competitive women’s health and immunology sector. In addition, she plans to attend the Bio€quity 2026 conference in Prague from May 4–6, a key forum for life sciences innovators, investors, and strategic partners.

Freya aims to use Bio€quity 2026 to engage with investors and potential partners and to discuss its pipeline of therapies targeting inflammation and immune dysregulation in women. While concrete financial outcomes will depend on future trial data and deal execution, expanded visibility and positive early clinical signals may support future fundraising and business development.

Overall, the week reflected meaningful momentum for Freya Biosciences, combining clinical advancement of FB301 with increasing scientific exposure and investor outreach that collectively strengthen its position in the women’s health space.